Oh yes—she is the best and there are professional organizations that say that, and those who support her work also back up their words of support with real hard-money support too—That’s why the NIH has supported her work for 20 consecutive years and is currently supporting with the recently renewed SPORE grant that is funding the Keytruda combo study.
The Keytruda study is significant and early data are starting to become available to the clinical investigators.
NCI and Merck are supporting as a collaborators of the murcidencel Keytruda combo study:
Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40
Group A (pembrolizumab, ATL-DC, poly ICLC) Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
Group B (placebo, ATL-DC, poly ICLC) Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.
News 
Market Data 
Discover 
